Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis
The presence of circulating tumor cells (CTCs) has been found to correlate with colorectal cancer (CRC) prognosis, whereas epithelial-mesenchymal transition (EMT) in CTCs has been found to be associated with CRC metastasis. LGR5 is a known target of Wnt signaling and plays an important role in CRC development. The aim of this study was to assess the clinical relevance of EMT and LGR5 expression in CTCs from CRC patients.
Sixty-six CRC patients were included in this study. The detection and expression of EMT phenotypes in CTCs from these patients were assessed using CanPatrol™ CTC enrichment and mRNA in situ hybridization (ISH), respectively. LGR5 expression in the CTCs was assessed using mRNA ISH.
CTCs were detected in 86.4% (57/66) of the CRC patients included. Both the numbers of total CTCs and of CTCs displaying a mesenchymal phenotype (M+ CTCs) were found to significantly correlate with advanced disease stages and the occurrence of metastasis (p < 0.05). An adjusted multivariate analysis also indicated that the number of M+ CTCs significantly correlated with the occurrence of metastasis (p = 0.031). Additionally, we found that a high LGR5 expression level significantly correlated with the occurrence of metastasis (p < 0.05). We also found that the presence of ≥ 6 CTCs or ≥ 3 M+ CTCs per 5 ml blood significantly correlated with disease progression (p < 0.05). Patients with ≥ 6 CTCs or ≥ 3 M+ CTCs per 5 ml blood were found to exhibit poorer progression-free survival (PFS) and overall survival (OS) rates (p < 0.05 in all cases). Using Cox regression analyses, we found that only total CTC numbers remained as independent prognostic factors for a worse PFS (p = 0.043).
From our data we conclude that CTC numbers and EMT phenotypes may serve as prognostic markers for disease progression and metastasis in CRC patients. In addition, we conclude that LGR5 expression in CTCs may serve as a marker for CRC metastasis.
KeywordsColorectal cancer (CRC) Circulating tumor cells (CTCs) Epithelial-mesenchymal transition (EMT) LGR5 expression
The authors sincerely thank all the investigators and coordinators who contributed to this study.
This study was supported by Guangzhou collaborative innovation major projects for “development and industrialization of key technology and product for tumor precision medical real time monitoring” (number 201604010039) and by Guangzhou health care collaborative innovation major projects for “development and industrialization of the clinical application of circulating tumor cell separation, typing and analysis of automatic equipment and reagents” (number 201604020014).
Compliance with ethical standards
Conflict of interest
The authors declare that there are no conflicts of interest.
All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University.
Informed consent was obtained from all the patients included in the study.
- 7.H. Imamura, Y. Matsuyama, E. Tanaka, T. Ohkubo, K. Hasegawa, S. Miyagawa, Y. Sugawara, M. Minagawa, T. Takayama, S. Kawasaki, M. Makuuchi, Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38, 200–207 (2003)CrossRefPubMedGoogle Scholar
- 11.J. Sastre, M.L. Maestro, J. Puente, S. Veganzone, R. Alfonso, S. Rafael, J.A. García-Saenz, M. Vidaurreta, M. Martín, M. Arroyo, M.T. Sanz-Casla, E. Díaz-Rubio, Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 19, 935–938 (2008)CrossRefPubMedGoogle Scholar
- 13.N.N. Rahbari, M. Aigner, K. Thorlund, N. Mollberg, E. Motschall, K. Jensen, M.K. Diener, M.W. Büchler, M. Koch, J. Weitz, Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 138, 1714–1726 (2010)CrossRefPubMedGoogle Scholar
- 15.S. Maheswaran, L.V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C.V. Collura, E. Inserra, S. Diederichs, A.J. Iafrate, D.W. Bell, S. Digumarthy, A. Muzikansky, D. Irimia, J. Settleman, R.G. Tompkins, T.J. Lynch, M. Toner, D.A. Haber, Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359, 366–377 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
- 16.E. Pailler, J. Adam, A. Barthélémy, M. Oulhen, N. Auger, A. Valent, I. Borget, D. Planchard, M. Taylor, F. André, J.C. Soria, P. Vielh, B. Besse, F. Farace, Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 31, 2273–2281 (2013)CrossRefPubMedGoogle Scholar
- 18.A. Merlos-Suarez, F.M. Barriga, P. Jung, M. Iglesias, M.V. Céspedes, D. Rossell, M. Sevillano, X. Hernando-Momblona, V. da Silva-Diz, P. Muñoz, H. Clevers, E. Sancho, R. Mangues, E. Batlle, The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8, 511–524 (2011)CrossRefPubMedGoogle Scholar
- 21.K. Tanese, M. Fukuma, T. Yamada, T. Mori, T. Yoshikawa, W. Watanabe, A. Ishiko, M. Amagai, T. Nishikawa, M. Sakamoto, G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol 173, 835–843 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
- 27.S. He, H. Zhou, X. Zhu, S. Hu, M. Fei, D. Wan, W. Gu, X. Yang, D. Shi, J. Zhou, J. Zhou, Z. Zhu, L. Wang, D. Li, Y. Zhang, Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. Biomed Pharmacother 68, 507–513 (2014)CrossRefPubMedGoogle Scholar
- 35.F.H. Shek, R. Luo, B.Y.H. Lam, W.K. Sung, T.W. Lam, J.M. Luk, M.S. Leung, K.T. Chan, H.K. Wang, C.M. Chan, R.T. Poon, N.P. Lee, Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma. Cell Oncol 40, 443–456 (2017)CrossRefGoogle Scholar